BioMarin Pharmaceutical's (BMRN) proposed acquisition of Amicus Therapeutics (FOLD) has been approved by the European Commission, the regulator said Tuesday.
The regulator said the pending transaction raised no competition concerns.
Under the deal announced in December, BioMarin will acquire Amicus for $14.50 per share in cash, valuing the company at about $4.8 billion.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments